Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency.
Journal: Journal of clinical immunology
Published: February 02, 2026
Clinical Evaluation of Pharmacokinetics, Efficacy, and Safety of a 10% Immunoglobulin in Primary Immunodeficiency Disease (CARES10 Study).
Journal: Advances in therapy
Published: November 30, 2025
A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency.
Journal: Journal of clinical immunology
Published: January 08, 2025
Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
Journal: Journal of clinical immunology
Published: March 08, 2024
Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
Journal: The journal of allergy and clinical immunology. In practice
Published: July 20, 2023
Towards an FDA-cleared basophil activation test.
Journal: Frontiers in allergy
Published: August 01, 2022
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Journal: The Journal of allergy and clinical immunology
Published: June 24, 2020
Validation of inducible basophil biomarkers: Time, temperature and transportation.
Journal: Cytometry. Part B, Clinical cytometry
Published: June 22, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026